- Home
- PHAT vs PAXS Comparison
PHAT vs PAXS Comparison
Compare PHAT & PAXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- PAXS
- Stock Information
- Founded
- PHAT 2018
- PAXS 2021
- Country
- PHAT United States
- PAXS United States
- Employees
- PHAT N/A
- PAXS N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- PAXS Investment Managers
- Sector
- PHAT Health Care
- PAXS Finance
- Exchange
- PHAT Nasdaq
- PAXS Nasdaq
- Market Cap
- PHAT 1.2B
- PAXS 757.3M
- IPO Year
- PHAT 2019
- PAXS N/A
- Fundamental
- Price
- PHAT $16.24
- PAXS $16.31
- Analyst Decision
- PHAT Strong Buy
- PAXS
- Analyst Count
- PHAT 4
- PAXS 0
- Target Price
- PHAT $22.50
- PAXS N/A
- AVG Volume (30 Days)
- PHAT 912.4K
- PAXS 195.0K
- Earning Date
- PHAT 11-07-2024
- PAXS 01-01-0001
- Dividend Yield
- PHAT N/A
- PAXS 11.72%
- EPS Growth
- PHAT N/A
- PAXS N/A
- EPS
- PHAT N/A
- PAXS N/A
- Revenue
- PHAT $9,918,000.00
- PAXS N/A
- Revenue This Year
- PHAT $6,512.02
- PAXS N/A
- Revenue Next Year
- PHAT $292.78
- PAXS N/A
- P/E Ratio
- PHAT N/A
- PAXS N/A
- Revenue Growth
- PHAT N/A
- PAXS N/A
- 52 Week Low
- PHAT $6.07
- PAXS $12.57
- 52 Week High
- PHAT $19.71
- PAXS $15.93
- Technical
- Relative Strength Index (RSI)
- PHAT 48.32
- PAXS 45.26
- Support Level
- PHAT $14.31
- PAXS $16.03
- Resistance Level
- PHAT $16.93
- PAXS $16.79
- Average True Range (ATR)
- PHAT 1.15
- PAXS 0.28
- MACD
- PHAT -0.20
- PAXS -0.10
- Stochastic Oscillator
- PHAT 41.42
- PAXS 23.14
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.